People seeking to end an early pregnancy will no longer need to physically visit a medical provider to receive the pill mifepristone as the Supreme Court weighs a case that will determine the fate of Roe v. Wade, the landmark ruling that legalized abortion nationwide.
The Food and Drug Administration’s Thursday decision will make it easier for women to access the drug, especially if Roe is overturned and states begin imposing additional abortion restrictions. The high court case, over a Mississippi law, had intensified pressure on the FDA to permanently nix the in-person dispensing rule for mifepristone.
The agency’s decision ...